Company Filing History:
Years Active: 1983-2006
Title: Norio Ohnishi: Innovator in Pharmaceutical Chemistry
Introduction
Norio Ohnishi is a distinguished inventor based in Kyoto, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of stable forms of bradykinin antagonists. With a total of 5 patents to his name, Ohnishi's work has had a notable impact on the medical industry.
Latest Patents
Ohnishi's latest patents include a vitreous form of a known bradykinin antagonist, specifically 8-[3-[N-[(E)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (FR173657). This invention is characterized by its good solid stability, making it suitable for producing and supplying FR173657 products that meet the quality standards necessary for medicinal use. The vitreous form of this compound ensures that the products maintain their stability and efficacy.
Career Highlights
Throughout his career, Ohnishi has worked with prominent companies in the pharmaceutical sector, including Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to innovative solutions in drug development.
Collaborations
Ohnishi has collaborated with notable colleagues such as Rinta Ibuki and Fumio Shimojo. These partnerships have facilitated the exchange of ideas and advancements in their respective fields.
Conclusion
Norio Ohnishi's contributions to pharmaceutical chemistry, particularly through his innovative patents, highlight his role as a key figure in the industry. His work continues to influence the development of stable medicinal products, ensuring quality and efficacy in healthcare.